BOTHELL, Wash.--(BUSINESS WIRE)-- MDRNA, Inc. (Nasdaq: MRNA) announced today positive in vivo efficacy data using a novel combination of a meroduplex siRNA and MDRNA’s proprietary lipid-based delivery platform, the DiLA2 Platform. The data presented today by Narendra Vaish, Ph.D., MBA, Senior Research Scientist and Group Leader - RNAi Platform Technologies at “RNA 2008,” the 13th Annual Meeting of the RNA Society in Berlin, Germany, indicate that a single iv administration of MDRNA meroduplexes targeting apolipoprotein B mRNA formulated in a DiLA2 delivery vehicle showed robust activity in a mouse model. The meroduplex siRNA decreased both ApoB mRNA and serum cholesterol levels. In addition, the formulated, chemically modified siRNA resulted in minimal body weight loss in mice while showing reduced levels of cytokine stimulation.
